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Eukaryotic cells possess a remarkable diversity of lipids, which distribute among cellularmembranes
by well-characterized vesicle trafficking pathways. However, transport of lipids by alternate, or
‘‘nonvesicular,’’ routes is also critical for lipid synthesis, metabolism, and propermembrane partition-
ing. In the past few years, considerable progress has beenmade in characterizing themechanisms of
nonvesicular lipid transport and how it may go awry in particular diseases, but many fundamental
questions remain for this rising field.A typical higher eukaryotic cell contains
more than 1000 different lipid species.
These lipids are not homogenously distrib-
uted among intracellular membranes, but
instead each organelle has a characteristic
lipid composition that is required for its
proper function. For example, cholesterol
and sphingolipids are highly enriched in
the plasma membrane and endosomes,
and indeed, many diseases, such as
atherosclerosis, type II diabetes, and lyso-
somal storage disorders, are associated
with defects in maintaining the correct
distribution of intracellular lipids. How do
these hydrophobic molecules shuttle
between intracellular membranes inside
the aqueous milieu of the cell?
Although trafficking largely determines
the intracellular distribution of most lipids,
we currently understand less about lipid
trafficking than we do about protein traf-
ficking. Nevertheless, proteins and lipids
do share similar properties. Both lipids
and integral membrane proteins move
between organelles in membrane-en-
closed sacs called transport vesicles,
and there is growing evidence that lipids,
like proteins, are sorted during the forma-
tion of transport vesicles.
However, unlike proteins, lipids can
rapidly and efficiently move between
cellularmembranes by routes independent
of transport vesicle, or ‘‘nonvesicular
transport’’ pathways. This important differ-
ence between protein and lipid trafficking
is not widely appreciated, in part, because
the roles and mechanisms of nonvesicular
lipid exchange have, in many cases, been870 Cell 143, December 10, 2010 ª2010 Elseobscure and difficult to characterize. In
the past few years, researchers have
made significant progress toward under-
standing how and why nonvesicular lipid
trafficking occurs. This Essay summarizes
the current state of the field and the major
challenges for its future.
How Much Nonvesicular Lipid
Trafficking Occurs in Cells?
The first studies suggesting the existence
of nonvesicular lipid exchange pathways
in the cell examined the movement of
newly synthesized lipids from the endo-
plasmic reticulum (ER), where they are
made, to the plasma membrane. Drugs
that halt vesicular trafficking do not stop
lipid transfer from the ER to the plasma
membrane, indicating that some lipids,
including phosphatidylcholine (PC),
phosphoatidylethanolamine (PE), choles-
terol, and glucosylceramide (GlcCer), can
move between the ER and plasma
membrane by nonvesicular pathways.
Moreover, these pathways have substan-
tial capacity because the rate of lipid
transfer does not decrease when vesic-
ular trafficking is blocked (Sleight and
Pagano, 1983; Kaplan and Simoni,
1985a, 1985b; Warnock et al., 1994).
Nevertheless, it remains unclear what
fraction of the lipid exchange between
the ER and plasma membrane is nonve-
sicular when vesicular trafficking is not
blocked.
More recently, studies have reported
strong evidence for nonvesicular transfer
of ceramides from the endoplasmic retic-vier Inc.ulum (ER) to the Golgi (Kok et al., 1998; Fu-
nato and Riezman, 2001; Hanada et al.,
2003), GlcCer transfer from the Golgi
complex to the ER and plasma membrane
(Halter et al., 2007; D’Angelo et al., 2007),
and sterols from the plasma membrane to
endocytic recyclingcompartment (Mesmin
and Maxfield, 2009). For example, studies
using dehydroergosterol, a fluorescent
analog of cholesterol, found that, when
this sterol is added to cells, it initially
incorporates into the plasma membrane
but then moves to the endocytic
recycling compartment by a nonvesicular,
energy-independent pathway. Dehydroer-
gosterol equilibrates between the
plasma membrane and endocytic recy-
cling compartment quite quickly—within
2–3 min—and astonishingly, an estimated
one million dehydroergosterol molecules
exchange between these compart-
ments each second (Maxfield andMondal,
2006).
Collectively, these and many other
studies indicate that the cell possesses
numerous pathways of nonvesicular lipid
transport, and more pathways will prob-
ably be discovered in the future. However,
in most cases, we still are uncertain about
of how much nonvesicular pathways
contribute to the total lipid exchange
inside of a cell. Are the nonvesicular path-
ways needed for exchanging a large
proportion of lipids between organelles,
or do only a small fraction of lipids
move by nonvesicular mechanisms? In
addition, some classes of lipids, such as
complex glycolipids, gangliosides, and
sphingolipids, may transfer by only vesic-
ular routes (Wattenberg, 1990; Hecht-
berger and Daum, 1995).
Roles of Nonvesicular Lipid
Trafficking in Cells
Nonvesicular lipid trafficking serves at
least four important functions in cells.
First, it provides lipids that are needed
for membrane biogenesis in organelles
that cannot obtain sufficient lipids from
vesicular trafficking. Mitochondria, chlo-
roplasts, and lipid droplets lack most of
the enzymes needed to make certain
lipids required for their biogenesis. These
organelles are not connected to the rest
of the cell by vesicular trafficking path-
ways and thus rely on nonvesicular traf-
ficking pathways to obtain these lipids.
Indeed, many studies show that lipids
exchange between the ER and mitochon-
dria or chloroplasts bynonvesicular routes
(Voelker, 2009; Benning, 2009). Less is
known about lipid transfer among lipid
droplets or between lipid droplets and
other organelles, but these pathways are
almost certainly nonvesicular as well.
There is also evidence for nonvesicular
lipid exchangebetween theERandperox-
isomes (Raychaudhuri and Prinz, 2008).
Nonvesicular transport also helps to
maintain the proper level of a lipid in an
organelle or domain of an organelle.
Compared to vesicular routes, one
obvious advantage of nonvesicular traf-
ficking is that it can rapidly move lipids
between specific compartments in cells
without having to also transfer integral
membrane proteins. This may be particu-
larly important for lipids, such as choles-
terol, which can be toxic to cells. Cells
use a number of mechanisms to rapidly
decrease cholesterol levels when they
are too high, such as effluxing cholesterol
out of cells to external lipoproteins and
producing cholesteryl esters (i.e., ester
linkages between the hydroxyl group of
cholesterol and the carboxylate group of
a fatty acid), which are stored in lipid drop-
lets. Nonvesicular transport of cholesterol
probably provides a route tomove choles-
terol quickly and efficiently to the enzymes
that perform these reactions without dis-
rupting vesicular trafficking.
Third, nonvesicular lipid trafficking may
also regulate lipid metabolism. For
example, the nonvesicular transfer of ce-
ramides from the ER, where they aresynthesized, to the Golgi complex, where
they are converted into glycolipids and
sphingolipids, may regulate the produc-
tion of these lipids. Finally, it is possible
that nonvesicular lipid transfer is required
for the transmission of a lipid as part of
a signaling or regulatory pathway. For
example, diacylglycerol activates protein
kinase C and ceramides serve as signal-
ing molecules to regulate differentiation,
proliferation, programmed cell death,
and apoptosis.
Mechanisms of Nonvesicular Lipid
Trafficking
Lipid monomers can exchange spontane-
ously between membranes by simply
diffusing through the aqueous phase
(Figure 1A). However, for most classes of
lipids, this process occurs too slowly to
be physiologically relevant; for example,
mostglycerolipids andsphingolipids spon-
taneously exchange between membranes
with half-times > 40 hr. The rate-limiting
step in this process is lipid desorption
from a membrane, and thus proteins that
accelerate lipid transfer may increase the
rate of lipid egress from the membrane.
Lipid transfer between membranes
may also occur when two membranes
collide (Figure 1B). Although the mecha-
nism of lipid exchange during collision is
not well understood, one model is that
a lipid must be ‘‘activated,’’ or partially
extended from the bilayer, prior to colli-
sion (Steck et al., 2002). This activation
increases the probability of transfer to
a second membrane during collision.
Activation could be stochastic, resulting
from the thermal motion that causes lipids
to bounce or bob in a bilayer, or it could be
mediated by a protein.
Proteins clearly facilitate the lipid non-
vesicular transport between membranes.
Although this process has been well char-
acterized in vitro, studies are only begin-
ning to unravel the mechanisms for these
pathways inside the cell (Voelker, 2009;
Benning, 2009). Nevertheless, in the three
cases described below, specific details
have emerged, including how defects in
these lipid trafficking pathways cause
disease.
CERT, a Typical Lipid Transport
Protein?
Ceramide is the precursor of sphingoli-
pids, including sphingomyelin, an abun-
dant lipid in the plasma membrane of allCell 143, Dmammalian cells. Sphingomyelin is
synthesized in the Golgi complex, but ce-
ramide is made in the ER. Therefore, to
produce sphingomyelin, ceramide must
be transported from the ER to the Golgi
complex, and this is accomplished by
CERT, the ceramide transport protein
(Hanada et al., 2009).
CERT is expressed ubiquitously in
higher eukaryotes, but it is not present in
yeast. CERT was identified from a mutant
cell line of Chinese hamster ovary cells,
called LY-A,which has low levels of sphin-
gomyelin (Hanada et al., 2003). Studies
found that, although LY-A mutant cells
make sphingomyelin at a reduced rate,
these cells produce normal amounts of
enzymes that synthesize sphingomyelin
(i.e., sphingomyelin synthase) and the
sphingomyelin precursors, ceramide and
PC. These results suggested that LY-A
cells have a defect in the nonvesicular
transfer of ceramide from the ER to the
Golgi complex. The gene that comple-
mented the cell’s defect was isolated
and named CERT. Disruption of the
CERT gene in mice results in death at
approximately embryonic day 11.5
(Wang et al., 2009), and flies lacking
CERThave a dramatic decrease in ceram-
ide phosphoethanolamine, the fly analog
of sphingomyelin (Rao et al., 2007).
CERT encodes a 68 kDa protein that
has three domains, an N-terminal PH
(pleckstrin homology) domain, a FFAT
(two phenylalanines in an acidic tract)
motif, and a C-terminal START (steroido-
genic acute regulatory protein [StAR]-
related) domain. The PH domain binds to
phosphoinositides (PIPs), whereas the
FFAT motif associates with proteins on
the ER called VAPs (vesicle-associated
membrane protein-associated proteins).
The START domain is the portion of the
protein that transports lipids, and it binds
a single molecule of ceramide in a hydro-
phobic cavity (Kudo et al., 2008).
CERT facilitates the movement of ce-
ramide between liposomes in vitro
(Hanada et al., 2003). The PH domain
and FFAT motif in CERT target it to the
ER and Golgi complex, respectively.
Thus, in vivo CERT probably extracts ce-
ramide from the ER, shuttles it through
the cytoplasm, and delivers it to the Golgi
complex. In general, proteins that
mediate lipid transfer by this mechanism
are called lipid transfer proteins (LTPs)ecember 10, 2010 ª2010 Elsevier Inc. 871
Figure 1. Possible Mechanisms of Nonvesicular Lipid Exchange between Membranes
(A and B) Lipids can spontaneously exchange between two membranes without the assistance of
proteins. (A) Monomers can diffuse through the aqueous phase or (B) during the collision of two-
membrane collision after the lipid is ‘‘activated.’’
(C–G) (C) Lipid transport proteins (LTPs) can also exchange lipids between membranes and organelles.
LTPs have a lipid-binding domain (blue) and, many times, targeting domains (purple) that may direct lipid
transfer to particular membranes by binding to lipids or proteins. Lipids may exchange at membrane
contact sites where two membranes come together in close proximity. Protein complexes may facilitate
this process (D) by forming a tunnel that allows lipids to diffuse between the membranes, (E) by promoting
lipid desorption from one membrane, (F) by activating lipids prior to membrane collision, or (G) by
promoting transient membrane hemifusion.(Figure 1C). The consumption of ceramide
in the Golgi complex to produce sphingo-
myelin probably drives the directionality
of the ceramide transport.
Ceramide transfer byCERT in vitro does
not require energy. Surprisingly, however,
ATP depletion blocks ceramide transport
by CERT in cells (Hanada et al., 2003),
and the role that energy plays in CERT
function in vivo remains an interesting,
unsolved mystery. The rate-limiting step
for ceramide transport by CERT is likely
diffusion through the cytosol. This is prob-
ably true of other LTPs as well.
Nevertheless, it is unlikely that CERT or
other LTPs diffuse long distances through
the cytosol. Rather, they probably operate872 Cell 143, December 10, 2010 ª2010 Elsemostly at regions where membranes are
closely apposed and come within
20 nm of each other. Called membrane
contact sites or MCSs, these junctions
are present ubiquitously in all cells and
are frequently found between the ER and
a second organelle (Levine and Loewen,
2006).
At membrane contact sites between
the ER and Golgi complex, CERT would
have to diffuse only a small distance, or
it may even bind both membranes simul-
taneously using its two targeting domains,
PH and FFAT (Hanada et al., 2009).
Although it is still unknown for certain
whether CERT localizes to membrane
contact sites between the ER and Golgivier Inc.complex, some LTPs are enriched at
these membrane junctions, including the
oxysterol-binding protein (OSBP) ORP1L
in mammals and most of the OSBP-
related proteins in yeast (theOsh proteins)
(Levine and Munro, 2001; Loewen et al.,
2003; Rocha et al., 2009; Schulz et al.,
2009).
CERT is part of a large family of proteins
that contain START domains, and many
members of this family can facilitate lipid
transfer between membranes in vitro. In
addition, there are approximately four
other large families of LTPs, andmost cells
express numerous LTPs (D’Angelo et al.,
2008; Lev, 2010). Some LTPs have high
specificity and bind only a few lipids,
whereas others can associatewith a broad
range of lipids. The different families of
LTPs are quite diverse, with few similarities
in sequence or structure. However, all
LTPs share the ability to bind lipid mono-
mers with a stoichiometry of one lipid for
each protein. In addition, all LTPs bind the
lipid monomer in a pocket covered with
a flexible ‘‘lid’’ domain that shields the
associated lipid from the aqueous phase
(Figure 1C). As with CERT, lipid exchange
by LTPs does not require energy.
A major controversy in the field is
whether the primary function of many
LTPs in cells is to transfer lipids between
membranes, as they do in vitro, or
whether they serve another main purpose
in cells. Aside from CERT, there is indeed
compelling evidence that other LTPs,
such as FAPP2 (Golgi-associated four-
phosphate adaptor protein 2), NPC2
(Niemann-Pick disease, type C2), and
some oxysterol-binding proteins in yeast,
transfer lipids in cells (Yamaji et al., 2008;
D’Angelo et al., 2008; Prinz, 2007). That
said, many LTPs do not appear to trans-
port lipids in cells but rather serve as lipid
sensors or regulate lipid metabolism and
signaling by presenting lipids tometabolic
enzymes. For example, the Sec14 super-
family of LTPs has been proposed to
present phosphoinositol to kinases that
produce PIPs, and thus these LTPs regu-
late many membrane trafficking and
signaling events that require PIPs (Bank-
aitis et al., 2010).
Lipid Exchange between the ER
and Mitochondria
Nonvesicular lipid trafficking that occurs
at membrane contact sites does not
always require soluble LTPs. Indeed, lipid
exchange between the ER and mitochon-
dria probably occurs independently of
LTPs. Lipid transport between these
organelles is critical for the synthesis of
phosphatidylcholine (PC) and phosphoa-
tidylethanolamine (PE), two of the most
abundant lipids in the membranes of
eukaryotes. In one of the two major path-
ways for producing PC, the first step is the
synthesis of phosphatidylserine (PS),
which occurs at the ER. PS is then trans-
ferred to the inner mitochondrial mem-
brane, where it is decarboxylated to
form PE, the precursor of PC. However,
the enzymes that convert PE to PC reside
back in the ER, and thus to make PC, the
PE must be returned to the ER from the
mitochondrial inner membrane. Conse-
quently, producing PE and PC by this
pathway requires multiple nonvesicular
lipid transfer steps. Remarkably, yeast
mutants that can make PE and PC solely
by this pathway grow as well as wild-
type cells and have similar levels of PE
and PC (Trotter et al., 1995). These results
indicate that nonvesicular lipid transfer
between ER and mitochondria must be
highly efficient.
Surprisingly, phospholipid exchange
between the ER and mitochondria
requires neither cytosolic factors nor
energy. It is thought to occur at special-
ized regions of the ER called mitochon-
dria-associated membranes (MAMs),
which are closely apposed to mitochon-
dria (Choi et al., 2006). An important ques-
tion in the field is how these membrane
contact sites form. Inmammals, a number
of proteins, such as mitofusins, GRP75
(glucose-regulated protein 75), and
PACS2 (phosphofurin acidic cluster sort-
ing protein 2), have been proposed to
mediate contacts between the MAM and
mitochondria, but whether any of these
proteins are needed for efficient lipid
exchange between these organelles is
not known (Lev, 2010). In yeast, studies
recently found that lipid transfer between
the ER and mitochondria slows down in
mutants missing a complex of four
proteins called the ERMES complex,
which bridges the ER and mitochondria
(Kornmann et al., 2009). Thus, maintaining
close contacts between the ER and mito-
chondria is required for efficient lipid
exchange between these organelles.
There are a number of ways in which
lipid transport exchange between the ERand mitochondria may occur at
membrane contact sites. First, protein
complexes in the two organelles could
interact to form a type of hydrophobic
tunnel or conduit that allows lipids to
passively diffuse between the two
membranes with little or no contact with
the aqueous phase (Figure 1D). Second,
a membrane protein complex at a contact
site could use energy to facilitate lipid
desorption from one of the membranes.
The probability that the lipid then diffuses
into the adjacent membrane is compa-
rable to that of it diffusingback into original
membrane (Figure 1E), leading to a net
transfer of lipid from one membrane to
the other. Third, if lipid transfer occurs by
an activated collision mechanism, then
aprotein complexcould alsopromote lipid
activation and increase the chance of lipid
exchange during membrane collision
(Figure 1F). Membranes at contact sites
may not be held a fixed distance and
may frequently collide. A fourth possibility
is that transmembrane proteins on two
different organelles bring two membranes
in close apposition so that they undergo
transient hemifusion (Figure 1G). Lipids
could then easily diffuse between the
hemifused membranes without contact-
ing the aqueous phase.
Defects in lipid transport to mitochon-
dria cause multiple diseases. For
example, some forms of congenital
adrenal hyperplasia, which is character-
ized by an impaired ability to produce the
steroid cortisol, are caused by defects in
cholesterol transport to the inner mito-
chondrial membranes. Steroids are
synthesized from cholesterol, and the first
step in this process occurs in the inner
mitochondrial membranes. Transporting
cholesterol to the inner mitochondrial
membranes requires the LTP StAR
(steroidogenic acute regulatory protein).
Although StAR binds cholesterol and can
transfer it between membranes in vitro
(Kallen et al., 1998), its role in cholesterol
transport in cells remains controversial. It
is not clear whether StAR moves choles-
terol from the outer to the inner mitochon-
drial membrane, moves cholesterol from
another organelle to the outer mitochon-
drial membrane, or regulates the proteins
that are actually responsible for choles-
terol transport to the inner mitochondrial
membrane. Such fundamental questions
need to be resolved before we can under-Cell 143, Dstandandbegin developing treatments for
many diseases caused by defects in lipid
transport.
Cholesterol Transfer by NPC1
and NPC2
Low-density lipoproteins (LDLs) transport
cholesterol and other lipids through the
bloodstream, and receptor-mediated
endocytosis of LDLs serves as a major
source of cholesterol in mammalian cells.
When endocytosed LDL reaches late en-
dosome/lysosome compartments, cho-
lesteryl esters in these particles are
hydrolyzed and the resulting cholesterol
is subsequently trafficked to the rest of
the cell. Nonvesicular mechanisms trans-
port cholesterol from internal membranes
to the outer membrane of the late endo-
some/lysosome and then eventually out
of the organelle.
Two proteins required for this type of
cholesterol transport are NPC1 and
NPC2. These proteins were identified by
studies on patients with Niemann-Pick
type C, a rare autosomal recessive lyso-
somal storage disease inwhich cholesterol
and other lipids accumulate in late endo-
somes/lysosomes. NPC1 is an integral
membrane protein with 13 putative trans-
membrane domains that reside in the
outer membrane of late endosomes/
lysosomes. In contrast, NPC2 is a small
soluble protein in the lumenof theseorgan-
elles. NPC2 is an LTP that facilitates
cholesterol transport betweenmembranes
in vitro (Cheruku et al., 2006). In cells, it
probably transfers cholesterol between
internal membranes in the late endosome/
lysosome and then hands it off to NPC1 in
the outer membrane (Infante et al., 2008;
Kwon et al., 2009; Wang et al., 2010).
NPC1 may then facilitate the egress of
cholesterol from the late endosome/
lysosome to other cellular compartments.
However, future studies are needed to
confirm this hypothesis and tocharacterize
exactly how NPC1 facilitates cholesterol
transfer to other cellular membranes.
Future
Many details of nonvesicular lipid traf-
ficking remain open questions and are
currently the focus of intense research.
However, a few concepts are clear. For
one, most nonvesicular lipid transfer prob-
ably occurs at membrane contact sites,
and undoubtedly, new techniques are
needed to study these junctions andecember 10, 2010 ª2010 Elsevier Inc. 873
identify proteins that function at these key
locations in thecell. Inaddition,asignificant
portion of lipid trafficking at membrane
contact sites probably does not require
soluble LTPs, but the mechanistic details
for how transfer occurs remain an impor-
tant question. Other fundamental issues
in this field include the energetics of nonve-
sicular lipid trafficking and its regulatory
mechanisms, including if andhow its direc-
tionality is determined. Answers to these
questions are imperative for understanding
howdefects in nonvesicular lipid trafficking
cause disease, but they are also critical for
deciphering fundamental processes in eu-
karyotic cells, including lipid metabolism,
signaling, and intracellular distribution.
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